RecruitingNot Applicable

Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

China200 participantsStarted 2020-12-22

Plain-language summary

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year);
✓. Age from 18 to 65 years old;
✓. Clinical diagnosis of liver failure (serum total bilirubin level \> 10 times upper limit of normal; prothrombin time activity \< 40% and ≥20%, or prothrombin time international ratio ≤ 2.6 and \> 1.5);
✓. Platelets \> 50\*10 E9/L.

Exclusion criteria

✕. Other active liver diseases;
✕. Hepatocellular carcinoma or other malignancy;
✕. Pregnancy or lactation;
✕. Human immunodeficiency virus infection or congenital immune deficiency diseases;
✕. Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events;
✕. Other important organ dysfunctions or transplantation;
✕. Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome;
✕. Patients can not follow-up;

What they're measuring

Mortality or liver transplantation rate

Timeframe: 12 weeks

Trial details

NCT IDNCT04597164

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Wenxiong Xu, Doctor

+8613760783281 xwx1983@163.com

View on ClinicalTrials.gov More Hepatitis B, Chronic trials